Ignoring a basic pathophysiological mechanism of heart failure progression will not make it go away

A link between heart failure (HF) and low thyroid hormone (TH) function has been known for over a century. Nonetheless, there is a general belief that TH treatment of patients with HF may not be worth the risk. This is largely based on two clinical trials where heart patients were treated with exces...

Full description

Saved in:
Bibliographic Details
Published inAmerican journal of physiology. Heart and circulatory physiology Vol. 320; no. 5; pp. H1919 - H1922
Main Authors Gerdes, A. Martin, Portman, Michael A., Iervasi, Giorgio, Pingitore, Alessandro, Cooper, David K. C., Novitzky, Dimitri
Format Journal Article
LanguageEnglish
Published United States American Physiological Society 01.05.2021
Subjects
Clinical trials
Congestive heart failure
Heart failure
Patients
Thyroid
heart failure
thyroid hormones
T3
Online AccessGet full text
ISSN0363-6135
1522-1539
1522-1539
DOI10.1152/ajpheart.00105.2021

Cover

More Information
Summary:A link between heart failure (HF) and low thyroid hormone (TH) function has been known for over a century. Nonetheless, there is a general belief that TH treatment of patients with HF may not be worth the risk. This is largely based on two clinical trials where heart patients were treated with excessive doses of TH analogs, not actual THs. Further complicating the matter is the fact that normalization of THs in noncardiac patients can often be challenging. This issue is not going away as noted by a steady increase in TH-HF citations in recent years. In this article, we discuss what we know and how we may move the field forward.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ObjectType-Editorial-2
ObjectType-Commentary-1
ISSN:0363-6135
1522-1539
1522-1539
DOI:10.1152/ajpheart.00105.2021